Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The ANZCTR website will be unavailable from 1pm until 3pm (AEDT) on Wednesday the 30th of October for website maintenance. Please be sure to log out of the system in order to avoid any loss of data.
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial registered on ANZCTR
Registration number
ACTRN12624001129572p
Ethics application status
Submitted, not yet approved
Date submitted
26/08/2024
Date registered
18/09/2024
Date last updated
18/09/2024
Date data sharing statement initially provided
18/09/2024
Type of registration
Prospectively registered
Titles & IDs
Public title
Evaluating Multiple Doses of an Optimized Subcutaneous Formulation of BHV-1300 in a Phase 1, Randomized, Open-Label, Placebo-Controlled Study
Query!
Scientific title
Evaluating Multiple Doses of an Optimized Subcutaneous Formulation of BHV-1300 in Healthy Adults in a Phase 1, Randomized, Open-Label, Placebo-Controlled Study
Query!
Secondary ID [1]
312677
0
None
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Autoimmune diseases
334665
0
Query!
Condition category
Condition code
Inflammatory and Immune System
331237
331237
0
0
Query!
Autoimmune diseases
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
BHV-1300 or placebo dosed once weekly for 4 doses.
500 mg of BHV-1300 will be administered as a subcutaneous injection. The dose will be administered while as an inpatient at the clinic by delegated study site personnel and documented in study notes.
Query!
Intervention code [1]
329204
0
Treatment: Drugs
Query!
Comparator / control treatment
The placebo to match BHV-1300 in appearance will be normal saline.
Query!
Control group
Placebo
Query!
Outcomes
Primary outcome [1]
339008
0
To assess the safety and tolerability of BHV-1300 following multiple dose SC administration. Safety and tolerability will be assessed as a composite primary outcome.
Query!
Assessment method [1]
339008
0
Safety and tolerability will be assessed by reporting the frequency of unique participants with Serious Adverse Events (SAEs); moderate or severe adverse events (AEs); and Grade 3-4 treatment-emergent laboratory abnormalities.
Potential side effects of this study drug in Phase 1 development are unknown. Any adverse events during the course of the study will be monitored.
Query!
Timepoint [1]
339008
0
AE's will be assessed daily from Screening through Day 26 and then on clinic visits on Day 36, Day 50, Day 64 and End of Treatment post-intervention commencement.
Vital signs will be assessed predose on Day 1, post dose on Days 2, 3, 4, 5, 6, and 7, predose on Day 8, post dose on on Days 9, 10, 11, 12, 13, and 14, predose on Day 15, postdose on on Days 16, 17, 18, 19, 20, and 21 and predose on Day 22 and postdose on Days 23, 24, 25, 26, 36, 50, and 64 and End of treatment clinic visit. Vital signs consist of blood pressure, heart rate, respiratory rate and temperature. These will be measured by sphygmomanometer, pulse oximeter and thermometer.
Query!
Secondary outcome [1]
438266
0
To characterize the PK profile of BHV-1300 following multiple dose SC administration
Query!
Assessment method [1]
438266
0
Blood plasma samples will be collected via venepuncture for PK samples. PK Parameters to be calculated following Day 1 will include AUC (0-t), AUC (0-inf), Cmax, Tmax, and T½. PK Parameters to be calculated following Day 22 will include AUC(0- t), AUC (0-inf), Cmax, Tmax, T½, RAAUC (0-t), and RACmax.
Query!
Timepoint [1]
438266
0
- Day 1: AUC (0-t), AUC (0-inf), Cmax, Tmax, and T½
- Day 22: AUC (0- t), AUC (0-inf), Cmax, Tmax, T½, RAAUC (0-t), and RACmax
Query!
Eligibility
Key inclusion criteria
1. Male or non-childbearing potential female, non-users of tobacco or nicotine products within 3 months prior to Screening, 18 to 55 years of age (inclusive), with BMI 18.0 to 30.0 kg/m2 (inclusive).
2. Healthy as defined by:
a. The absence of clinically significant illness and surgery within 12 weeks prior to dosing.
b. The absence of clinically significant history of neurological, endocrine, cardiovascular, respiratory, hematological, immunological, psychiatric, gastrointestinal, hepatobiliary, renal, and metabolic disease.
Query!
Minimum age
18
Years
Query!
Query!
Maximum age
55
Years
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
Yes
Query!
Key exclusion criteria
1. History of a clinically significant bacterial, fungal, parasitic, viral, or mycobacterial infection within 90 days prior to screening.
2. History of recurrent respiratory tract infections (including bronchitis, viral or bacterial pneumonia, sinusitis).
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
Randomised controlled trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Allocation is not concealed. Participants will be randomized to receive BHV-1300 or Placebo according to the randomisation schedule prepared prior to study start.
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Sequence generation will be performed by simple randomisation using a randomisation table created by computer software.
Query!
Masking / blinding
Query!
Who is / are masked / blinded?
Query!
Query!
Query!
Query!
Intervention assignment
Query!
Other design features
Query!
Phase
Phase 1
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Not yet recruiting
Query!
Date of first participant enrolment
Anticipated
28/10/2024
Query!
Actual
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
Query!
Actual
Query!
Sample size
Target
8
Query!
Accrual to date
Query!
Final
Query!
Recruitment in Australia
Recruitment state(s)
VIC
Query!
Funding & Sponsors
Funding source category [1]
317111
0
Commercial sector/Industry
Query!
Name [1]
317111
0
Biohaven Therapeutics Limited
Query!
Address [1]
317111
0
Query!
Country [1]
317111
0
United States of America
Query!
Primary sponsor type
Commercial sector/Industry
Query!
Name
Biohaven Therapeutics Limited
Query!
Address
Query!
Country
United States of America
Query!
Secondary sponsor category [1]
319369
0
Commercial sector/Industry
Query!
Name [1]
319369
0
Avance Clinical Pty Ltd
Query!
Address [1]
319369
0
Query!
Country [1]
319369
0
Australia
Query!
Ethics approval
Ethics application status
Submitted, not yet approved
Query!
Ethics committee name [1]
315860
0
Alfred Hospital Ethics Committee
Query!
Ethics committee address [1]
315860
0
https://www.alfredhealth.org.au/research/ethics-research-governance
Query!
Ethics committee country [1]
315860
0
Australia
Query!
Date submitted for ethics approval [1]
315860
0
04/09/2024
Query!
Approval date [1]
315860
0
Query!
Ethics approval number [1]
315860
0
Query!
Summary
Brief summary
BHV-1300 is being developed by Biohaven Therapeutics Limited for the potential treatment of immune-mediated diseases. This is a single center, Phase 1, randomized, open-label, placebo controlled, multiple dose study in healthy adults. This study will include 1 multiple dose cohort to evaluate the safety and tolerability of BHV-1300 and to characterize the pharmacokinetic profile of BHV-1300.
Query!
Trial website
Query!
Trial related presentations / publications
Query!
Public notes
Query!
Contacts
Principal investigator
Name
136018
0
Dr Sam Francis
Query!
Address
136018
0
Nucleus Network Pty Ltd, Level 5, Burnet Tower, 89 Commercial Rd, Melbourne, VIC 3004
Query!
Country
136018
0
Australia
Query!
Phone
136018
0
+61 385939800
Query!
Fax
136018
0
Query!
Email
136018
0
[email protected]
Query!
Contact person for public queries
Name
136019
0
Sam Francis
Query!
Address
136019
0
Nucleus Network Pty Ltd, Level 5, Burnet Tower, 89 Commercial Rd, Melbourne, VIC 3004
Query!
Country
136019
0
Australia
Query!
Phone
136019
0
+61 385939800
Query!
Fax
136019
0
Query!
Email
136019
0
[email protected]
Query!
Contact person for scientific queries
Name
136020
0
Sam Francis
Query!
Address
136020
0
Nucleus Network Pty Ltd, Level 5, Burnet Tower, 89 Commercial Rd, Melbourne, VIC 3004
Query!
Country
136020
0
Australia
Query!
Phone
136020
0
+61 385939800
Query!
Fax
136020
0
Query!
Email
136020
0
[email protected]
Query!
Data sharing statement
Will individual participant data (IPD) for this trial be available (including data dictionaries)?
No
Query!
No/undecided IPD sharing reason/comment
Query!
What supporting documents are/will be available?
No Supporting Document Provided
Results publications and other study-related documents
Documents added manually
No documents have been uploaded by study researchers.
Documents added automatically
No additional documents have been identified.
Download to PDF